Fisetin: a powerful senolytic in mice, unproven in humans

Fisetin sits at the exciting frontier of aging research — senolytics, the idea that you can slow aging by clearing the worn-out cells that accumulate and poison their neighbors. The mouse data is real and impressive. The human data, for the thing fisetin is actually sold to do, barely exists yet. Keeping those two facts side by side is the entire job of this monograph.

What it is and the senolytic idea

Fisetin is a flavonoid — a plant polyphenol found in strawberries, apples and other foods — long sold as a general antioxidant supplement. Its modern interest is as a senolytic. As we age, some cells stop dividing but refuse to die, becoming “senescent” — metabolically active “zombie” cells that secrete inflammatory signals and degrade the tissue around them. Senolytics aim to selectively killthose cells while sparing healthy ones. The landmark study screened ten flavonoids and found fisetin was the most potent senolytic, reducing senescence markers across multiple tissues and, when given to old mice, restoring tissue health and extending both median and maximum lifespan.^[1] It also cleared senescent cells in human fat tissue tested in a dish.^[1]

The mouse evidence is strong — and it’s mouse evidence

The preclinical record has held up on replication. An independent 2025 study found intermittent fisetin reduced frailty and improved grip strength in old mice, while having no effect in young mice — consistent with a senolytic mechanism acting on accumulated senescent cells.^[2]This is exactly the kind of clean, age-specific result that makes fisetin compelling. The catch is in the species.

The human data that does exist isn’t about senolysis

Fisetin has been in a few small human studies — but not for aging. The only published human pharmacokinetic work simply measured how well it’s absorbed (it’s poorly bioavailable, the reason formulations exist), in 15 healthy volunteers with no adverse events.^[5]Small randomized trials have tested fisetin as an add-on in colorectal cancer and ischemic stroke, where it lowered some inflammatory markers — useful signals, but they tell you nothing about clearing senescent cells or slowing aging in healthy people. Don’t let the existence of “human fisetin trials” be mistaken for evidence of the senolytic claim.

Safety and status

Fisetin is a flavonoid with a long history of dietary exposure, and the small human study reported no adverse events.^[5] That said, the high, intermittent “senolytic” doses people take are different from dietary amounts, and their long-term human safety hasn’t been established. It is sold as a dietary supplement, not an approved drug; its senolytic use is explicitly investigational, which is precisely why the ongoing trials matter.

The honest bottom line

Fisetin is one of the best-supported senolytics in mice — potent, age-specific, with lifespan and frailty data behind it.^[1][2] But for the use that sells it, the human evidence is not weak so much as not yet here: the trials that would prove or disprove a senolytic benefit in people are still running.^[3][4] It’s a reasonable compound to watch, and a safe-seeming flavonoid — but anyone marketing it as a proven anti-aging therapy is selling mouse data as a human result. For longevity compounds that have reached human trials, contrast it with urolithin A and spermidine.